logo
Select company
Select metric
$ -129.93MEarnings Before Interest Taxes & Depreciation Amortization (EBITDA)
VS
Market
6
Sector
14
Industry
21
History
29
$ 11.73Close
$ 5.31 - $ 12.34 52-Week Range
Ticker Information

Ticker

RGNX

Company Name

REGENXBIO INC

Sector

Healthcare

Industry

Biotechnology

Exchange

NASDAQ

REGENXBIO INC - Earnings Before Interest Taxes & Depreciation Amortization (EBITDA) Chart Analysis (TTM)

From
Zoom
1Y
3Y
5Y
10Y

RGNX - EBITDA Historical data
DateDepreciation, Amortization & AccretionEarning Before Interest & Taxes (EBIT)Earnings Before Interest Taxes & Depreciation Amortization (EBITDA)
6/30/2025$ 15.84M$ -145.77M$ -129.93M
3/31/2025$ 15.99M$ -138.43M$ -122.44M
12/31/2024$ 16.21M$ -214.44M$ -198.23M
9/30/2024$ 16.53M$ -234.35M$ -217.82M
6/30/2024$ 16.94M$ -235.82M$ -218.88M
3/31/2024$ 17.32M$ -254.22M$ -236.9M
12/31/2023$ 17.32M$ -256.78M$ -239.46M
9/30/2023$ 17.11M$ -250.77M$ -233.66M
6/30/2023$ 16.29M$ -260.06M$ -243.77M
3/31/2023$ 14.5M$ -250.44M$ -235.94M
Previous (option currently disabled)
1 (current)
Next (option currently disabled)

Key Performance Insights, Last 5 Years

  • REGENXBIO INC's latest trailing twelve months (TTM) EBITDA stands at $ -86.14M.
  • Over the past 5 years, REGENXBIO INC's average EBITDA has been $ -115.32M.
  • The median EBITDA for REGENXBIO INC during this period was $ -153.5M
  • REGENXBIO INC reached its highest EBITDA over the past 5 years at $ 177.09M.
  • The lowest EBITDA recorded by REGENXBIO INC in the same timeframe $ -244.24M

REGENXBIO INC's EBITDA vs. competitors

We picked the following companies as peers based on multiple factors, including sector, industry, market capitalization and revenue

EBITDA Benchmarks
CompanyEBITDA
CTMX : CYTOMX THERAPEUTICS INC $ 54.08MXNCR : XENCOR INC $ -123.36MARCT : ARCTURUS THERAPEUTICS HOLDINGS INC $ -72.27MYMAB : Y-MABS THERAPEUTICS INC $ -26.3MGLUE : MONTE ROSA THERAPEUTICS INC $ 36.76MHRTX : HERON THERAPEUTICS INC $ 3.88MNKTR : NEKTAR THERAPEUTICS $ -94.15MPACB : PACIFIC BIOSCIENCES OF CALIFORNIA INC $ -112.13MLXRX : LEXICON PHARMACEUTICALS INC $ -107.44MVNDA : VANDA PHARMACEUTICALS INC $ -77.06M

Similar metrics to EBITDA:

Definition of Earnings Before Interest Taxes & Depreciation Amortization (EBITDA)

[Calculation] EBITDA is a non-GAAP accounting metric that lets investors asses profitability net of expenses dependent on financing decision, tax strategy and depreciation schedules. It is calculated by adding depreciation and amortisation expenses [DepAmor] back to [EBIT].
EBIT + DepAmor
(=) EBITDA EBITDA for REGENXBIO INC is calculated as follows: EBIT [ $ -94.37M ] + DepAmor [ $ 8.22M ]
(=) EBITDA [ $ -86.14M ]

RGNX - Earnings Before Interest Taxes & Depreciation Amortization (EBITDA), Last 5 years

$ -244.24M

Minimum

Dec 31, 2022

$ 177.09M

Maximum

Dec 31, 2021

$ -115.32M

Average

$ -153.5M

Median

EBITDA Benchmark Analysis

 The chart above depicts the distribution of EBITDA for companies in the Total Stock Market. The average EBITDA of the companies is $ 58.79M with a standard deviation of $ 166.94M.
The following table provides additional summary stats:
EBITDA in the Market:
filtered constituents3.25K
min$ -493.3M
max$ 590.6M
average$ 58.79M
median$ 8.83M
std$ 166.94M